Class Action Cases

Nektar Therapeutics

Join Class Action »

According to the Complaint, the Company made false and misleading statements to the market. Nektar’s clinical-stage drug NKTR-214 faced multiple issues, and the Company’s attempt to improve it by “pegylating” IL-2 failed. The Company did not disclose that previous studies attempting to pegylate IL-2 also failed. The extended half-life for NKTR-214 was unlikely to provide benefits and also created safety concerns.  NKTR-214 was less effective than IL-2 by itself. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Nektar, investors suffered damages.

Press Release

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, October 31, 2018 — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between November 11, 2017 and October 2, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before December 31, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Nektar’s clinical-stage drug NKTR-214 faced multiple issues, and the Company’s attempt to improve it by “pegylating” IL-2 failed. The Company did not disclose that previous studies attempting to pegylate IL-2 also failed. The extended half-life for NKTR-214 was unlikely to provide benefits and also created safety concerns. NKTR-214 was less effective than IL-2 by itself. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Nektar, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com
310-301-3335
info@schallfirm.com

SOURCE:
The Schall Law Firm